Analyst Price Targets — INCY
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 18, 2026 10:10 am | — | Barclays | $117.00 | $101.16 | TheFly | Incyte price target raised to $117 from $116 at Barclays |
| February 11, 2026 2:09 pm | — | Morgan Stanley | $102.00 | $98.45 | TheFly | Incyte price target raised to $102 from $94 at Morgan Stanley |
| February 11, 2026 12:14 pm | Stephen Willey | Stifel Nicolaus | $120.00 | $100.05 | TheFly | Incyte price target raised to $120 from $119 at Stifel |
| February 6, 2026 11:52 am | Allison Bratzel | Piper Sandler | $110.00 | $102.76 | TheFly | Incyte price target raised to $110 from $102 at Piper Sandler |
| February 5, 2026 11:05 am | — | H.C. Wainwright | $135.00 | $102.60 | TheFly | Incyte initiated with a Buy at H.C. Wainwright |
| February 4, 2026 10:46 am | — | Barclays | $116.00 | $100.92 | TheFly | Incyte price target raised to $116 from $115 at Barclays |
| January 20, 2026 10:19 am | — | Wells Fargo | $107.00 | $106.21 | TheFly | Incyte downgraded to Equal Weight from Overweight at Wells Fargo |
| January 8, 2026 12:39 pm | — | Goldman Sachs | $90.00 | $110.57 | TheFly | Incyte price target raised to $90 from $80 at Goldman Sachs |
| January 5, 2026 6:33 pm | Stephen Willey | Stifel Nicolaus | $119.00 | $101.79 | StreetInsider | Stifel Reiterates Buy Rating on Incyte (INCY) |
| December 24, 2025 12:08 pm | Srikripa Devarakonda | Truist Financial | $103.00 | $100.91 | TheFly | Incyte price target raised to $103 from $93 at Truist |
Latest News for INCY
AE Wealth Management LLC purchased a new stake in Incyte Corporation (NASDAQ: INCY) during the fourth quarter, according to its most recent disclosure with the SEC. The firm purchased 26,995 shares of the biopharmaceutical company's stock, valued at approximately $2,666,000. A number of other hedge funds and other institutional investors have also recently
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Merit Financial Group LLC increased its holdings in Incyte Corporation (NASDAQ: INCY) by 41.7% in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 49,806 shares of the biopharmaceutical company's stock after purchasing an additional 14,659 shares during the period. Merit Financial Group
KBC Group NV decreased its position in Incyte Corporation (NASDAQ: INCY) by 37.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 267,394 shares of the biopharmaceutical company's stock after selling 157,700 shares during the quarter. KBC Group NV owned
WILMINGTON, Del.--(BUSINESS WIRE)--1Q Alert.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.